WHAT IS CLAIMED IS:

1. Use of an agent capable of inhibiting NBL1 activity in the manufacture of a medicament for delaying onset or progression of kidney damage in a subject who has type 1 diabetes or type 2 diabetes or a glomerular disease.

2. The use of claim 1, wherein the agent is capable of binding to NBL1.

3. The use of claim 2, wherein the agent is capable of binding to human NBL1.

4. The use of claim 3, wherein the agent is an antibody, or an antigen binding fragment of an antibody, that is capable of binding to human NBL1.

5. The use of claim 4, wherein the antibody or antigen-binding fragment comprises three heavy chain CDRs and three light chain CDRs

having sequences selected from:

a) SEQ ID NOs: 3, 8, and 13 and SEQ ID NOs: 18, 23, and 28 (antibody E05);

b) SEQ ID NOs: 33, 38, and 43 and SEQ ID NOs: 48, 53, and 58 (antibody H08);

c) SED ID NOs: 63, 68, and 73 and SED ID NOs: 78, 83, and 88 (antibody F06);

d) SEQ ID NOs: 93, 98, and 103 and SEQ ID NOs: 108, 113, and 118 (antibody A12);

e) SED ID NOs: 123, 128, and 133 and SED ID NOs: 138, 143, and 148 (antibody G01);

f) SED ID NOs: 153, 158, and 163 and SED ID NOs: 168, 173 and 178 (antibody E11);

g) SEQ ID NOs: 183, 188, and 193 and SEQ ID NOs: 198, 203, and 208 (antibody B06);

h) SED ID NOs: 213, 218, and 223 and SED ID NOs: 228, 233, and 238 (antibody D12);

i) SED ID NOs: 243, 248, and 253 and SED ID NOs: 258, 263 and 268 (antibody H01);

j) SED ID NOs: 273, 278, and 283 and SED ID NOs: 288, 293, and 298 (antibody C11);

k) SED ID NOs: 303, 308, and 313 and SED ID NOs: 318, 323, and 328 (antibody E05);

l) SED ID NOs:333, 338, and 343 and SED ID NOs: 348, 353 and 358 (antibody F10);

m) SED ID NOs: 363, 368 and 373 and SED ID NOs: 378, 383 and 388 (antibody G10);

n) SEQ ID NOs: 393, 398, and 403 and SEQ ID NOs: 408, 413, and 418 (antibody E04);

o) SED ID NOs: 423, 428, and 433 and SED ID NOs: 438, 443, and 448 (antibody E07);

p) SEQ ID NOs: 453, 458, and 463 and SED ID NOs: 468, 473, and 478 (antibody E12);

q) SED ID NOs: 483, 488, and 493 and SED ID NOs: 498, and 503, and 508 (antibody D08);

r) SED ID NOs: 513, 518, and 523 and SED ID NOs: 528, 533, and 538 (antibody E10);

s) SEQ ID NOs: 543, 548, and 553 and SEQ ID NOs: 558, 563, and 568 (antibody D06); and

t) SED ID NOs: 573, 578, and 583 and SED ID NOs: 588, 593, and 598 (antibody E01),

or having sequences that differ from the selected CDR sequences (a) – (t) by at most two conservative amino acid substitutions in each CDR.

6. The use of claim 5, wherein the antibody or antigen-binding fragment comprises three heavy chain CDRs and three light chain CDRs with sequences identical to the selected CDRs.

7. The use of claim 5 or claim 6, wherein the three heavy chain CDRs and three light chain CDRs have sequences selected from:

b) SEQ ID NOs: 33, 38, and 43 and SEQ ID NOs: 48, 53 and 58 (antibody H08);

d) SEQ ID NOs: 93, 98, and 103 and SEQ ID NOs: 108, 113, and 118 (antibody A12);

g) SEQ ID NOs: 183, 188, and 193 and SEQ ID NOs: 198, 203, and 208 (antibody B06);

n) SEQ ID NOs: 393, 398, and 403 and SEQ ID NOs: 408, 413, and 418 (antibody E04);

s) SEQ ID NOs: 543, 548, and 553 and SEQ ID NOs: 558, 563, and 568 (antibody D06); and

t) SEQ ID NOs: 573, 578, and 583 and SEQ ID NOs: 588, 593, and 598 (antibody E01),

or having sequences that differ from the selected CDR sequences b), d), g), n) s), and t) by at most two conservative amino acid substitutions in each CDR.

8. The use of claim 7, wherein the antibody or antigen-binding fragment comprises three heavy chain CDRs and three light chain CDRs with sequences identical to the selected CDRs.

9. The use of any one of claims 4-8, wherein the antibody framework regions are human antibody framework regions.

10. The use of any one of claims 4-9, wherein the antibody is a full length bivalent monospecific monoclonal antibody.

11. The use of claim 10, wherein the antibody comprises human IgG1, IgG2, or IgG4 heavy chain constant regions.

12. The use of claim 11, wherein the antibody comprises a human IgG1 constant region.

13. The use of any one of claims 10-12, wherein the antibody Fc region has engineered mutations that reduce antibody binding to at least one type of Fc receptor and/or reduce complement fixation.

14. The use of any one of claims 4-9, wherein the antibody is a Fab, optionally wherein the Fab is PEGylated.

15. The use of any one of claims 4-14, wherein the antibody or antigen binding fragment is further capable of binding to cynomolgus monkey NBL1.

16. The use of claim 15, wherein the antibody or antigen binding fragment is further capable of binding to mouse NBL1.

17. The use of any one of claims 4-17, wherein the antibody or antigen binding fragment has a binding affinity (K_D) for human NBL1 of less than 100 nM.

18. The use of claim 17, wherein the antibody or antigen binding fragment has a binding affinity (K_D) for human NBL1 of less than 10 nM.

19. The use of claim 18, wherein the antibody or antigen binding fragment has a binding affinity (K_D) for human NBL1 of less than 5 nM.

20. The use of any one of claims 1-3, wherein the agent comprises a bone morphogenetic protein (BMP) or soluble fragment thereof.

21. The use of claim 20, wherein the agent comprises a soluble fragment of human BMP-2.

22. The use of claim 20 or claim 21, wherein the agent further comprises a moiety that extends serum half-life.

23. The use of claim 22, wherein the half-life extension moiety is an antibody Fc domain.

24. The use of claim 22, wherein the half-life extension moiety is at least one covalently linked polyethylene glycol (PEG) moiety.

25. The use of any one of claims 1-24, wherein the agent is capable of inhibiting dimerization of NBL1.

26. The use of claim 1, wherein the agent is capable of inhibiting NBL1 expression.

27. The use of any one of claims 1-26, wherein the agent is to be administered parenterally.

28. The use of claim 27, wherein the agent is to be administered intravenously.

29. The use of claim 27, wherein the agent is to be administered subcutaneously.

30. The use of any one of claims 1-29, wherein the agent is to be administered for at least 3 months.

31. The use of claim 30, wherein the agent is to be administered for at least 6 months.

32. The use of claim 31, wherein the agent is to be administered for at least 12 months.

33. The use of any one of claims 1-32, wherein the subject has elevated pre-treatment plasma levels of NBL1.

34. The use of any one of claims 1-33, wherein the subject has type 1 diabetes.

35. The use of any one of claims 1-33, wherein the subject has type 2 diabetes.

36. The use of any one of claims 1-35, wherein the subject has a glomerular disease.

37. The use of claim 36, wherein the subject with glomerular disease does not have type 1 diabetes or type 2 diabetes.

38. The use of claim 36 or claim 37, wherein the glomerular disease is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), chronic glomerulopathies, hereditary nephritis, and minimal change disease.

39. The use of any one of claims 1-38, wherein the medicament prevents onset of or slows decline in kidney function.

40. Use of an agent capable of inhibiting NBL1 activity in the manufacture of a medicament for treating diabetic kidney disease (DKD) or a glomerular disease in a subject who has type 1 or type 2 diabetes or a glomerular disease.

41. The use of claim 40, wherein the agent is an antibody, or antigen binding fragment of an antibody, that is capable of binding to human NBL1.

42. An antibody or antigen binding fragment, wherein the antibody is capable of binding to NBL1 and inhibiting NBL1-induced toxicity of human podocytes.

43. The antibody of claim 42, wherein the antibody or antigen-binding fragment comprises three heavy chain CDRs and three light chain CDRs

having sequences selected from:

a) SEQ ID NOs: 3, 8, and 13 and SEQ ID NOs: 18, 23, and 28 (antibody E05);

b) SEQ ID NOs: 33, 38, and 43 and SEQ ID NOs: 48, 53, and 58 (antibody H08);

c) SED ID NOs: 63, 68, and 73 and SED ID NOs: 78, 83, and 88 (antibody F06);

d) SEQ ID NOs: 93, 98, and 103 and SEQ ID NOs: 108, 113, and 118 (antibody A12);

e) SED ID NOs: 123, 128, and 133 and SED ID NOs: 138, 143, and 148 (antibody G01);

f) SED ID NOs: 153, 158, and 163 and SED ID NOs: 168, 173 and 178 (antibody E11);

g) SEQ ID NOs: 183, 188, and 193 and SEQ ID NOs: 198, 203, and 208 (antibody B06);

h) SED ID NOs: 213, 218, and 223 and SED ID NOs: 228, 233, and 238 (antibody D12);

i) SED ID NOs: 243, 248, and 253 and SED ID NOs: 258, 263 and 268 (antibody H01);

j) SED ID NOs: 273, 278, and 283 and SED ID NOs: 288, 293, and 298 (antibody C11);

k) SED ID NOs: 303, 308, and 313 and SED ID NOs: 318, 323, and 328 (antibody E05);

l) SED ID NOs:333, 338, and 343 and SED ID NOs: 348, 353 and 358 (antibody F10);

m) SED ID NOs: 363, 368 and 373 and SED ID NOs: 378, 383 and 388 (antibody G10);

n) SEQ ID NOs: 393, 398, and 403 and SEQ ID NOs: 408, 413, and 418 (antibody E04);

o) SED ID NOs: 423, 428, and 433 and SED ID NOs: 438, 443, and 448 (antibody E07);

p) SED ID NOs: 453, 458, and 463 and SED ID NOs: 468, 473, and 478 (antibody E12);

q) SED ID NOs: 483, 488, and 493 and SED ID NOs: 498, and 503, and 508 (antibody D08);

r) SED ID NOs: 513, 518, and 523 and SED ID NOs: 528, 533, and 538 (antibody E10);

s) SEQ ID NOs: 543, 548, and 553 and SEQ ID NOs: 558, 563, and 568 (antibody D06); and

t) SED ID NOs: 573, 578, and 583 and SED ID NOs: 588, 593, and 598 (antibody E01),

or having sequences that differ from the selected CDR sequences (a) – (t) by at most two conservative amino acid substitutions in each CDR.

44. The antibody or antigen binding fragment of claim 43, wherein the antibody or antigen-binding fragment comprises three heavy chain CDRs and three light chain CDRs with sequences identical to the selected CDRs.

45. The antibody or antigen binding fragment of claim 43 or claim 44, wherein the three heavy chain CDRs and three light chain CDRs have sequences selected from:

b) SEQ ID NOs: 33, 38, and 43 and SEQ ID NOs: 48, 53 and 58 (antibody H08);

d) SEQ ID NOs: 93, 98, and 103 and SEQ ID NOs: 108, 113, and 118 (antibody A12);

g) SEQ ID NOs: 183, 188, and 193 and SEQ ID NOs: 198, 203, and 208 (antibody B06);

n) SEQ ID NOs: 393, 398, and 403 and SEQ ID NOs: 408, 413, and 418 (antibody E04);

s) SEQ ID NOs: 543, 548, and 553 and SEQ ID NOs: 558, 563, and 568 (antibody D06); and

t) SEQ ID NOs: 573, 578, and 583 and SEQ ID NOs: 588, 593, and 598 (antibody E01),

or having sequences that differ from the selected CDR sequences b), d), g), n) s), and t) by at most two conservative amino acid substitutions in each CDR.

46. The antibody or antigen binding fragment of claim 45, wherein the antibody or antigen-binding fragment comprises three heavy chain CDRs and three light chain CDRs with sequences identical to the selected CDRs.

47. The antibody or antigen binding fragment of any one of claims 43-46, wherein the antibody framework regions are human antibody framework regions.

48. The antibody or antigen binding fragment of any one of claims 43-47, wherein the antibody is a full length bivalent monospecific monoclonal antibody.

49. The antibody or antigen binding fragment of claim 48, wherein the antibody comprises human IgG1, IgG2, or IgG4 heavy chain constant regions.

50. The antibody or antigen binding fragment of claim 49, wherein the antibody comprises a human IgG1 constant region.

51. The antibody or antigen binding fragment of any one of claims 48-50, wherein the antibody Fc region has engineered mutations that reduce antibody binding to FcRγ and/or reduce complement fixation.

52. The antibody or antigen binding fragment of any one of claims 43-47, wherein the antibody is a Fab, optionally wherein the Fab is PEGylated.

53. The antibody or antigen binding fragment of any one of claims 42-52, wherein the antibody or antigen binding fragment is further capable of binding to cynomolgus monkey NBL1.

54. The antibody or antigen binding fragment of claim 53, wherein the antibody or antigen binding fragment is further capable of binding to mouse NBL1.

55. The antibody or antigen binding fragment of any one of claims 42-54, wherein the antibody or antigen binding fragment has a binding affinity (K_D) for human NBL1 of less than 100 nM.

56. The antibody or antigen binding fragment of claim 55, wherein the antibody or antigen binding fragment has a binding affinity (K_D) for human NBL1 of less than 10 nM.

57. The antibody or antigen binding fragment of claim 55, wherein the antibody or antigen binding fragment has a binding affinity (K_D) for human NBL1 of less than 5 nM.

58. A pharmaceutical composition, comprising:
the antibody or antigen binding fragment of any one of claims 42-57, and
a pharmaceutically acceptable carrier.

59. The pharmaceutical composition of claim 58, wherein the composition is formulated for parenteral administration.

60. The pharmaceutical composition of claim 59, wherein the composition is formulated for intravenous administration.

61. The pharmaceutical composition of claim 59, wherein the composition is formulated for subcutaneous administration.